The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release

Jacob Golenser, Abraham Domb, Doron Teomim, Appolinaire Tsafack, Orna Nisim, Prem Ponka, Wijnand Eling, Z. Ioav Cabantchik

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

The hydrophilic desferrioxamine (DFO) and the lipophilic salicylaldehyde isonicotinoyl hydrazone (SIH) are iron chelators which inhibit in vitro proliferation of Plasmodium falciparum with similar potency (IC50 ~20 μM in 24- to 48-h tests). The in vivo assessment of these drugs was performed on Swiss mice infected with Plasmodium vinckei petteri with novel modes of drug administration and release. The drugs were delivered postpatently either by multiple i.p. injections or by a single i.p. or s.c. insertion of a drug- containing polymeric device which released most of the drug within 7 days at apparently first-order rates. A regimen of three daily i.p injections of 5 mg DFO for 3 consecutive days or a 70-mg dose of the drug given as an i.p. or s.c. polymer implant evoked similar delay and reduction in peak parasitemias and reduced mortality with no apparent signs of toxicity. Relatively faster, but otherwise similar results were obtained with the less hydrophilic SIH. In combination, the two drugs apparently potentiated each other. The polymeric devices were particularly useful for treating Plasmodium berghei K173- infected C57BI mice, a suggested model of cerebral malaria, in which classical methods of DFO delivery were ineffective. The insertion of a 140- mg DFO-containing device on day 6 postinfection (parasitemia ~1%) led to a marked reduction in parasite proliferation, appearance of neurological sequelae and mortality of mice. Our studies indicate that polymeric devices for slow drug release might be highly advantageous for both hydrophilic and lipophilic drugs whose antimalarial efficacy might depend on the maintenance of sustained blood levels. The results obtained with slow-release devices have implications for malaria chemotherapy as well as for iron chelation therapy in iron overload conditions.

Original languageEnglish
Pages (from-to)1127-1135
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume281
Issue number3
StatePublished - Jun 1997
Externally publishedYes

Funding

FundersFunder number
National Institute of Allergy and Infectious DiseasesR01AI020342

    Fingerprint

    Dive into the research topics of 'The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release'. Together they form a unique fingerprint.

    Cite this